Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma

BACKGROUND: The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O(6)-methylguanine-DNA methyltransferase (MGMT)-nonmethylated glioblastoma, showed that progression-free survival was significantly pr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Schäfer, Niklas, Proescholdt, Martin, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter, Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Grau, Stefan, Hänel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Nießen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin, Herrlinger, Ulrich
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Clinical Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007398/
https://ncbi.nlm.nih.gov/pubmed/29121274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox204
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia